EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Melanie J Davies, Harpreet S Bajaj, Christa Broholm, Astrid Eliasen, W Timothy Garvey, Carel W le Roux, Ildiko Lingvay iD, Christian Bøge Lyndgaard, Julio Rosenstock iD, Sue D Pedersen, REDEFINE 2 Study Group

New England Journal of Medicine · 14.08.2025 · 393 (7) · 648-659

DOI: 10.1056/nejmoa2502082 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 14.08.2025. Verfasst von Melanie J Davies und 10 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Centre, University of Leicester, Leicester, United Kingdom. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Overweight, Weight Loss. Die Arbeit wurde bisher 158-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ObesityOverweightWeight LossGlucagon-Like Peptide-1 Receptor AgonistsIslet Amyloid PolypeptideAdultAgedFemaleHumansMaleMiddle AgedBlood GlucoseBody Mass IndexDouble-Blind MethodGlycated HemoglobinHypoglycemiaLife StyleDrug CombinationsTreatment OutcomeIntention to Treat AnalysisContinuous Glucose MonitoringGlucagon-Like Peptide 1Semaglutide

Substanzen

Blood GlucoseGlycated HemoglobinGlucagon-Like Peptide-1 Receptor AgonistsIslet Amyloid PolypeptideDrug CombinationsGlucagon-Like Peptide 1Semaglutidecagrilintide

Autor:innen und Institutionen

  • Diabetes Research Centre, University of Leicester, Leicester, United Kingdom.
  • NIHR Leicester Biomedical Research Centre, Leicester, United Kingdom.
  • Endocrine and Metabolic Research, LMC Healthcare, Brampton, ON, Canada.
  • Novo Nordisk, Søborg, Denmark.
  • Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham.
  • Diabetes Complications Research Centre, University College Dublin School of Medicine, Dublin.

ORCID-Profile: Ildiko Lingvay, Julio Rosenstock

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., Pedersen, S. D., & REDEFINE 2 Study Group (2025). Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine, 393(7), 648-659. https://doi.org/10.1056/nejmoa2502082

Vancouver

Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. 2025;393(7):648-659. doi:10.1056/nejmoa2502082

BibTeX
@article{Davies2025,
  author = {Davies, Melanie J and Bajaj, Harpreet S and Broholm, Christa and Eliasen, Astrid and Garvey, W Timothy and le Roux, Carel W and Lingvay, Ildiko and Lyndgaard, Christian Bøge and Rosenstock, Julio and Pedersen, Sue D and REDEFINE 2 Study Group, REDEFINE 2 Study Group},
  title = {Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {7},
  pages = {648--659},
  doi = {10.1056/nejmoa2502082}
}
Kostenlos starten →